Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):283–286. doi: 10.1038/bjc.1989.58

Circulating CA 15-3 antigen levels in non-mammary malignancies.

R Colomer 1, A Ruibal 1, J Genollà 1, L Salvador 1
PMCID: PMC2246988  PMID: 2930693

Abstract

Abnormal CA 15-3 antigen levels are found in the serum of most patients with advanced breast carcinoma. Elevations of this marker are less frequently seen in other malignancies. Circulating CA 15-3 levels might be useful in the differential diagnosis of the primary site of cancer. We studied the levels of CA 15-3 in 500 patients with different non-mammary cancers. Elevations of CA 15-3 (greater than 40 U ml-1) were observed in all types of epithelial malignancies, especially in ovarian (46%), respiratory (26%) and liver (30%) carcinomas. Abnormal values were observed in some patients with haematological malignancies and sarcomas, but not in melanoma or neurological tumours. CA 15-3 antigen levels correlated with the extent of non-mammary malignant tumours. Patients with locoregional cancer had a significantly smaller proportion of elevations of the antigen than those with distant metastases (12% versus 35%, P less than 0.001). In particular, elevated CA 15-3 levels were observed in 70% of patients with metastatic ovarian cancer. Liver involvement by cancer did not produce more elevations of CA 15-3 than metastases to other organs (32% versus 39%). Simultaneous determination of circulating CA 15-3 and CA 125 antigens in 58 patients with cancer of the ovary showed that CA 15-3 is elevated in some cases of ovarian carcinoma with non-elevated CA 125, and that CA 15-3 and CA 125 are distinct antigens. We conclude that circulating CA 15-3 antigen levels can be found elevated in virtually all types of cancer, particularly when distant metastases are present. Therefore, CA 15-3 levels should not be used in the differential diagnosis of the primary site in patients with metastatic malignancies of unknown origin. Evaluation of CA 15-3 levels may enhance the sensitivity of CA 125 in monitoring the course of ovarian carcinoma.

Full text

PDF
284

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe M., Kufe D. W. Identification of a family of high molecular weight tumor-associated glycoproteins. J Immunol. 1987 Jul 1;139(1):257–261. [PubMed] [Google Scholar]
  2. Friedman E. L., Hayes D. F., Kufe D. W. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res. 1986 Oct;46(10):5189–5194. [PubMed] [Google Scholar]
  3. Gion M., Mione R., Dittadi R., Fasan S., Pallini A., Bruscagnin G. Evaluation of CA15/3 serum levels in breast cancer patients. J Nucl Med Allied Sci. 1986 Jan-Mar;30(1):29–36. [PubMed] [Google Scholar]
  4. Hayes D. F., Sekine H., Ohno T., Abe M., Keefe K., Kufe D. W. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest. 1985 May;75(5):1671–1678. doi: 10.1172/JCI111875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hayes D. F., Zurawski V. R., Jr, Kufe D. W. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986 Oct;4(10):1542–1550. doi: 10.1200/JCO.1986.4.10.1542. [DOI] [PubMed] [Google Scholar]
  6. Hilkens J., Buijs F., Hilgers J., Hageman P., Calafat J., Sonnenberg A., van der Valk M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984 Aug 15;34(2):197–206. doi: 10.1002/ijc.2910340210. [DOI] [PubMed] [Google Scholar]
  7. Hilkens J., Kroezen V., Bonfrer J. M., De Jong-Bakker M., Bruning P. F. MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res. 1986 May;46(5):2582–2587. [PubMed] [Google Scholar]
  8. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984 Fall;3(3):223–232. doi: 10.1089/hyb.1984.3.223. [DOI] [PubMed] [Google Scholar]
  9. Pons-Anicet D. M., Krebs B. P., Mira R., Namer M. Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer. 1987 May;55(5):567–569. doi: 10.1038/bjc.1987.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ruibal A., Genollá J., Rosell M., Moragas G. El CA 15.3-ELSA sérico en patologías no tumorales. Med Clin (Barc) 1987 Mar 21;88(11):476–476. [PubMed] [Google Scholar]
  11. Sekine H., Hayes D. F., Ohno T., Keefe K. A., Schaetzl E., Bast R. C., Knapp R., Kufe D. W. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol. 1985 Oct;3(10):1355–1363. doi: 10.1200/JCO.1985.3.10.1355. [DOI] [PubMed] [Google Scholar]
  12. Yoshimoto M., Akiyama F., Watanabe S., Kasumi F., Fukami A., Nakajima T., Nishi M., Kajitani T., Takahashi S. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer]. Gan To Kagaku Ryoho. 1987 Jul;14(7):2310–2315. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES